Treatment

Recent oncology developments have introduced several innovative therapies across solid and blood cancers, offering new treatment options for patients with previously limited choices. Inlexzo, an FDA-approved gemcitabine intravesical system, provides extended local delivery for adults with BCG-unresponsive non-muscle invasive bladder cancer, reducing the need for repeated procedures. Ifinatamab deruxtecan (I-DXd), a B7-H3 directed antibody-drug conjugate,

Recent innovations in rectal cancer surgery emphasize precision, reduced invasiveness, and preservation of function. Minimally invasive techniques such as laparoscopic surgery, robotic-assisted surgery, and single-incision laparoscopic surgery (SILS) allow smaller incisions, less pain, faster recovery, and improved dexterity in confined pelvic spaces. Organ- and function-preserving approaches, including transanal total mesorectal excision (TaTME), sphincter-sparing procedures, and

Recent innovations in early-stage breast cancer care (stages 0-3) are shifting toward personalized, precision treatments that reduce recurrence risk while minimizing side effects and improving quality of life. Key Advances: Targeted Therapies are replacing broad chemotherapy approaches. Antibody-Drug Conjugates like Kadcyla deliver chemotherapy directly to cancer cells, while kinase inhibitors like Neratinib block growth signals. New

For patients with advanced basal cell carcinoma (BCC) not curable by surgery, combining targeted drug therapy with radiation offers strong tumor control and long-term benefits. The drug (a Hedgehog pathway inhibitor like vismodegib) shrinks tumors and makes them more sensitive to radiation, while radiation destroys remaining cancer cells. A Phase II trial in patients with

The AnnAraC combination of annamycin and cytarabine demonstrated encouraging activity in AML patients in the phase 1/2 MB-106 trial, suggesting potential survival benefits. Across first- through seventh-line settings, the median overall survival (OS) was nine months in the 22-patient intention-to-treat population. Patients achieving complete remission (CR, n=8) had a median OS of 15 months, with

PThe phase 3 monarchE trial demonstrates that adjuvant abemaciclib combined with two years of endocrine therapy significantly improves overall survival in high-risk, node-positive HR+/HER2– early breast cancer patients. The 7-year landmark analysis confirmed sustained benefits in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS). monarchE enrolled 5,637 patients across two cohorts. Cohort 1 (n=5,120)

Darolutamide (Nubeqa) is a novel therapy for metastatic castration-sensitive prostate cancer (mCSPC), a stage where cancer has spread but remains responsive to testosterone-lowering treatments. As a highly selective androgen receptor antagonist, it blocks male hormones that drive tumor growth while minimizing neurological side effects due to its limited penetration of the blood-brain barrier. The drug

Recent approvals in gastrointestinal and genitourinary cancers are expanding treatment options with more precise and effective therapies. Pembrolizumab (Keytruda), a PD-1 checkpoint inhibitor, is now approved for colorectal, gastric, and esophageal cancers, showing durable responses, improved survival, and better quality of life for biomarker-selected patients. Trastuzumab (Herceptin), targeting HER2, benefits patients with HER2-positive gastric and

Recent advances in non-muscle-invasive bladder cancer (NMIBC) offer several innovative therapies, particularly for patients unresponsive to BCG treatment. These options leverage gene therapy, immune stimulation, oncolytic viruses, and novel drug delivery systems to improve outcomes. Nadofaragene firadenovec is an FDA-approved gene therapy that delivers a modified virus into bladder cells, prompting them to produce interferon